AgeX Therapeutics Inc. (AGE)
AgeX Therapeutics Statistics
Share Statistics
AgeX Therapeutics has 2.5M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 2.5M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.45M |
| Failed to Deliver (FTD) Shares | 104 |
| FTD / Avg. Volume | 2.61% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.99 and the forward PE ratio is null. AgeX Therapeutics's PEG ratio is -0.03.
| PE Ratio | -0.99 |
| Forward PE | n/a |
| PS Ratio | 102.88 |
| Forward PS | null |
| PB Ratio | 2.67 |
| P/FCF Ratio | -1.87 |
| PEG Ratio | -0.03 |
Enterprise Valuation
AgeX Therapeutics has an Enterprise Value (EV) of 18.63M.
| EV / Sales | 131.19 |
| EV / EBITDA | -1.9 |
| EV / EBIT | -2.39 |
| EV / FCF | -2.39 |
Financial Position
The company has a current ratio of 0.13, with a Debt / Equity ratio of 0.8.
| Current Ratio | 0.13 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.8 |
| Debt / EBITDA | -0.44 |
| Debt / FCF | -0.56 |
| Interest Coverage | -2.03 |
Financial Efficiency
Return on Equity is -270.67% and Return on Invested Capital is -101.23%.
| Return on Equity | -270.67% |
| Return on Assets | -123.72% |
| Return on Invested Capital | -101.23% |
| Revenue Per Employee | $35.5K |
| Profits Per Employee | $-3.7M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8K |
| Effective Tax Rate | 0.05% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.19, so AgeX Therapeutics's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 13.98 |
| 200-Day Moving Average | 20.11 |
| Relative Strength Index (RSI) | 41.05 |
| Average Volume (20 Days) | 3.98K |
Income Statement
In the last 12 months, AgeX Therapeutics had revenue of 142K and earned -14.8M in profits. Earnings per share was -13.72.
| Revenue | 142K |
| Gross Profit | -29K |
| Operating Income | -9.96M |
| Net Income | -14.8M |
| EBITDA | -9.83M |
| EBIT | -9.84M |
| Earnings Per Share (EPS) | -13.72 |
Balance Sheet
The company has 345K in cash and 4.37M in debt, giving a net cash position of -4.02M.
| Cash & Cash Equivalents | 345K |
| Total Debt | 4.37M |
| Net Cash | -4.02M |
| Retained Earnings | -131.01M |
| Total Assets | 10.86M |
| Working Capital | -5.12M |
Cash Flow
In the last 12 months, operating cash flow was -7.8M and capital expenditures 0, giving a free cash flow of -7.8M.
| Operating Cash Flow | -7.8M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.8M |
| FCF Per Share | -7.23 |
Margins
Gross margin is -20.42%, with operating and profit margins of -7014.08% and -10424.65%.
| Gross Margin | -20.42% |
| Operating Margin | -7014.08% |
| Pretax Margin | -10430.28% |
| Profit Margin | -10424.65% |
| EBITDA Margin | -6921.83% |
| EBIT Margin | -7014.08% |
| FCF Margin | -5492.96% |
Dividends & Yields
AGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -101.32% |
| FCF Yield | -53.39% |
Analyst Forecast
Currently there are no analyst rating for AGE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 15, 2024. It was a backward split with a ratio of 100:3517.
| Last Split Date | Mar 15, 2024 |
| Split Type | backward |
| Split Ratio | 100:3517 |
Scores
| Altman Z-Score | -3.24 |
| Piotroski F-Score | 4 |